Discovery of highly potent and selective type I B-Raf kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 23, 2009, Pages 6571-6574

  Wang, Xiaolun ^a   Berger, Dan M ^a   Salaski, Edward J ^a   Torres, Nancy ^a   Hu, Yongbo ^a   Levin, Jeremy I ^a   Powell, Dennis ^a   Wojciechowicz, Donald ^a   Collins, Karen ^a   Frommer, Eileen ^a  

^a WYETH RESEARCH   (United States)

Author keywords

B Raf; Inhibitors; Kinase; Raf; RAS

Indexed keywords

ENZYME; PYRIMIDINE DERIVATIVE; RAF PROTEIN;

ARTICLE; CONCENTRATION (PARAMETERS); ENZYME ACTIVE SITE; ENZYME CONFORMATION; HUMAN; HUMAN CELL; MOLECULAR MODEL;

DRUG DISCOVERY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 71749100660     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.030     Document Type: Article

References (14)

1. Wellbrock C., Karasarides M., and Marais R. Nat. Rev. Mol. Cell. Biol. 5 (2004) 875
2. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Nature 417 (2002) 949
3. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. Cancer Res. 64 (2004) 7099
4. Takle A.K., Brown M.J.B., Davies S., Dean D.K., Francis G., Gaiba A., Hird A.W., King F.D., Lovell P.J., Naylor A., Reith A.D., Steadman J.G., and Wilson D.M. Bioorg. Med. Chem. Lett. 16 (2006) 378
5. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., Kumar R., Rusnak D.W., Takle A.K., Wilson D.M., Hugger E., Wang L., Karreth F., Lougheed J.C., Lee J., Chau D., Stout T.J., May E.W., Contractor R.G., Smalley K.S.M., Herlyn M., Morrissey M.M., Tuveson D.A., and Huang P. Cancer Res. 66 (2006) 11100
6. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S.M., Fong D., Zhu Y.-L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.-H., Schlessinger J., Zhang K.Y.J., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., and Bollag G. Proc. Natl. Acad. Sci. 105 (2008) 3041
7. Venetsanakos, E.; Stuart, D.; Tan, N.; Ye, H.; Salangsang, F.; Aardalen, K.; Faure, M; Heise, C.; Mendel, D.; Jallal, B. CHIR-265, No.4854 A Novel Inhibitor that Targets B-Raf and VEGFR, Shows Efficacy in a Broad Range of Preclinical Models. 97th AACR Annual Meeting. April 1-5, 2006; Washington DC, USA.
8. Schwartz, G.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D. S.; Shannon, P.; Gordon, M. S. No. 3513 A Phase 1 Study of Xl281, A Selective Inhibitor of RAF Kinases, Administered Orally to Patients with Advanced Solid Tumors 2009 ASCO Annual Meeting, May 29-June 2, 2009; Orlando, FL, USA.
9. Gopalsamy A., Ciszewski G., Hu Y., Lee F., Feldberg L., Frommer E., Kim S., Collins K., Wojciechowicz D., and Mallon R. Bioorg. Med. Chem. Lett. 19 (2009) 2735
10. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Cell 116 (2004) 855
11. 3c was used.
12. For a related series, see: MEDI 137 Substituted pyrazolo[5,1-c][1,2,4]triazines as potent B-Raf kinase inhibitors. Berger, D. M.; Dutia, M.; Hopper, D. W.; Torres, N.; Powell, D. W.; Hu, Y.; Frommer, E.; Collins, K.; Wojciechowicz, D. Fall 2009 ACS National Meeting, August 16-20, 2009; Washington, DC, USA.
13. For assay conditions, see Ref. 4.
14. DiGrandi, M. J.; Berger, D. M.; Hopper, D. W.; Zhang, C.; Dutia, M.; Dunnick, A. L.; Torres, N.; Levin, J. I.; Diamantidis, G.; Zapf, C.; Bloom, J. D.; Hu, Y.; Powell, D.; Wojciechowicz, D.; Collins, K.; Frommer, E. Bioorg. Med. Chem. Lett., accepted for publication.